,address1,address2,city,zip,country,phone,fax,website,industry,sector,longBusinessSummary,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,recommendationKey,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,"No. 138, Xinming Road",7th Floor Neihu District,Taipei,11470,Taiwan,886 2 8177 7020,886 2 2796 3606,https://www.taigenbiotech.com.tw,Biotechnology,Healthcare,"TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. It is also developing Taigexyn for treating community-acquired pneumonia and diabetic foot infection, as well as other bacterial infections; Burixafor, a stem cell mobilizer for stem cell transplantation and chemosenzitization; TG-1000, an influenza antiviral drug for treating influenza A, B, and avian influenza H7N9; and Furaprevir, a hepatitis C virus protease inhibitor for the treatment of chronic hepatitis C. The company was founded in 2001 and is based in Taipei City, Taiwan.","{'maxAge': 1, 'name': 'Dr. Ming-Chu  Hsu Ph.D.', 'title': 'Founder', 'fiscalYear': 2014, 'totalPay': 15000, 'exercisedValue': 0, 'unexercisedValue': 0}",1419984000,86400,2,15.1,15.1,14.8,15.15,15.1,15.1,14.8,15.15,0.0,0.835438,906810,906810,2491444,602600,602600,14.9,14.95,0,0,10716818432,13.45,18.75,83.01369,15.412,15.52425,0.0,0.0,TWD,9933345792,-1.09889,472450490,716844032,0.35933,0.2494,1.328,11.25753,1672444800,1703980800,1688083200,-141863008,-0.2,76.945,-80.904,TWO,EQUITY,4157.TWO,4157.TWO,TAIGEN BIOPHARMACEUTICALS HLDGS,TaiGen Biopharmaceuticals Holdings Limited,1377824400,Asia/Taipei,CST,28800000,14.95,none,866022016,1.208,-122780000,82547000,18.825,19.229,129097000,8.669,0.18,-0.07221,-0.13685,32494000,-125179000,-176271008,36.032,0.93336,-0.95107,-1.03041,TWD,
1,"No. 138, Xinming Road",7th Floor Neihu District,Taipei,11470,Taiwan,886 2 8177 7020,886 2 2796 3606,https://www.taigenbiotech.com.tw,Biotechnology,Healthcare,"TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. It is also developing Taigexyn for treating community-acquired pneumonia and diabetic foot infection, as well as other bacterial infections; Burixafor, a stem cell mobilizer for stem cell transplantation and chemosenzitization; TG-1000, an influenza antiviral drug for treating influenza A, B, and avian influenza H7N9; and Furaprevir, a hepatitis C virus protease inhibitor for the treatment of chronic hepatitis C. The company was founded in 2001 and is based in Taipei City, Taiwan.","{'maxAge': 1, 'name': 'Mr. Kuo-Lung  Huang', 'title': 'Chairman, CEO, Pres & Chief Commercial Officer in Asia', 'exercisedValue': 0, 'unexercisedValue': 0}",1419984000,86400,2,15.1,15.1,14.8,15.15,15.1,15.1,14.8,15.15,0.0,0.835438,906810,906810,2491444,602600,602600,14.9,14.95,0,0,10716818432,13.45,18.75,83.01369,15.412,15.52425,0.0,0.0,TWD,9933345792,-1.09889,472450490,716844032,0.35933,0.2494,1.328,11.25753,1672444800,1703980800,1688083200,-141863008,-0.2,76.945,-80.904,TWO,EQUITY,4157.TWO,4157.TWO,TAIGEN BIOPHARMACEUTICALS HLDGS,TaiGen Biopharmaceuticals Holdings Limited,1377824400,Asia/Taipei,CST,28800000,14.95,none,866022016,1.208,-122780000,82547000,18.825,19.229,129097000,8.669,0.18,-0.07221,-0.13685,32494000,-125179000,-176271008,36.032,0.93336,-0.95107,-1.03041,TWD,
2,"No. 138, Xinming Road",7th Floor Neihu District,Taipei,11470,Taiwan,886 2 8177 7020,886 2 2796 3606,https://www.taigenbiotech.com.tw,Biotechnology,Healthcare,"TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. It is also developing Taigexyn for treating community-acquired pneumonia and diabetic foot infection, as well as other bacterial infections; Burixafor, a stem cell mobilizer for stem cell transplantation and chemosenzitization; TG-1000, an influenza antiviral drug for treating influenza A, B, and avian influenza H7N9; and Furaprevir, a hepatitis C virus protease inhibitor for the treatment of chronic hepatitis C. The company was founded in 2001 and is based in Taipei City, Taiwan.","{'maxAge': 1, 'name': 'Mr. Richard  Lu', 'title': 'VP of Fin.', 'exercisedValue': 0, 'unexercisedValue': 0}",1419984000,86400,2,15.1,15.1,14.8,15.15,15.1,15.1,14.8,15.15,0.0,0.835438,906810,906810,2491444,602600,602600,14.9,14.95,0,0,10716818432,13.45,18.75,83.01369,15.412,15.52425,0.0,0.0,TWD,9933345792,-1.09889,472450490,716844032,0.35933,0.2494,1.328,11.25753,1672444800,1703980800,1688083200,-141863008,-0.2,76.945,-80.904,TWO,EQUITY,4157.TWO,4157.TWO,TAIGEN BIOPHARMACEUTICALS HLDGS,TaiGen Biopharmaceuticals Holdings Limited,1377824400,Asia/Taipei,CST,28800000,14.95,none,866022016,1.208,-122780000,82547000,18.825,19.229,129097000,8.669,0.18,-0.07221,-0.13685,32494000,-125179000,-176271008,36.032,0.93336,-0.95107,-1.03041,TWD,
3,"No. 138, Xinming Road",7th Floor Neihu District,Taipei,11470,Taiwan,886 2 8177 7020,886 2 2796 3606,https://www.taigenbiotech.com.tw,Biotechnology,Healthcare,"TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. It is also developing Taigexyn for treating community-acquired pneumonia and diabetic foot infection, as well as other bacterial infections; Burixafor, a stem cell mobilizer for stem cell transplantation and chemosenzitization; TG-1000, an influenza antiviral drug for treating influenza A, B, and avian influenza H7N9; and Furaprevir, a hepatitis C virus protease inhibitor for the treatment of chronic hepatitis C. The company was founded in 2001 and is based in Taipei City, Taiwan.","{'maxAge': 1, 'name': 'Dr. Peter W. Tsao M.B.A., Ph.D., MBA', 'title': 'VP Corp. Devel.', 'exercisedValue': 0, 'unexercisedValue': 0}",1419984000,86400,2,15.1,15.1,14.8,15.15,15.1,15.1,14.8,15.15,0.0,0.835438,906810,906810,2491444,602600,602600,14.9,14.95,0,0,10716818432,13.45,18.75,83.01369,15.412,15.52425,0.0,0.0,TWD,9933345792,-1.09889,472450490,716844032,0.35933,0.2494,1.328,11.25753,1672444800,1703980800,1688083200,-141863008,-0.2,76.945,-80.904,TWO,EQUITY,4157.TWO,4157.TWO,TAIGEN BIOPHARMACEUTICALS HLDGS,TaiGen Biopharmaceuticals Holdings Limited,1377824400,Asia/Taipei,CST,28800000,14.95,none,866022016,1.208,-122780000,82547000,18.825,19.229,129097000,8.669,0.18,-0.07221,-0.13685,32494000,-125179000,-176271008,36.032,0.93336,-0.95107,-1.03041,TWD,
